Figure 2.
Targeted nanotherapy suppresses K/ BxN serum-induced arthritis. Arthritis was induced by intraperitoneal injection of K/BxN serum, and arthritis development (A) and changes in ankle thickness (B) were monitored daily by two independent observers. Starting on d 2 after serum transfer, when arthritis was clearly established in all animals, mice were given 3 daily intravenous doses of either αvβ3-targeted nps without drugs or αvβ3-targeted nps with 1.5 mol% fumagillin. Another control group received no treatment. Values are means ± se; n = 6–7 mice/group. *P < 0.05; **P < 0.01; ***P < 0.001.